The short version of c-Met receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Labour Party leader Sir Keir Starmer publishes details of his tax returns, a day after the prime minister. The Westminster Parliament announces that the TikTok app will be banned on "all parliamentary devices and the wider parliamentary network". The British Medical Association announces that junior doctors in England will stage a four-day strike from 11 to 15 April in their continued quest for a 35% pay rise. England footballer Harry Kane becomes the England national football team all-time leading goalscorer with 54 goals in a 2–1 win vs Italy national football team, surpassing the previous record of 53 goals held by Wayne Rooney, who broke the record back in September 2015. 24 March Charles III's state visit to France, his first official overseas visit as King, is postponed following a request by French president Emmanuel Macron after unions threatened to stage a day of protests over pension reforms during his visit. MPs vote to back the Protection from Sex-based Harassment in Public Bill, which will make catcalling, following someone or blocking their path an offence in England and Wales with a punishment of up to two years in prison. COVID-19 in the UK: The final Coronavirus Infections Survey is published by the Office for National Statistics, with data for the week up to 13 March. It shows an increase in COVID-19 cases for England, but an uncertain picture for the rest of the UK.
Tetrahymanol is a gammacerane-type membrane lipid first found in the marine ciliate Tetrahymena pyriformis. It was later found in other ciliates, fungi, ferns, and bacteria. After being deposited in sediments that compress into sedimentary rocks over millions of years, tetrahymanol is dehydroxylated into gammacerane. Gammacerane has been interpreted as a proxy for ancient water column stratification.
=== Combinatorial extension === The combinatorial extension (CE) method is similar to DALI in that it too breaks each structure in the query set into a series of fragments that it then attempts to reassemble into a complete alignment. A series of pairwise combinations of fragments called aligned fragment pairs, or AFPs, are used to define a similarity matrix through which an optimal path is generated to identify the final alignment. Only AFPs that meet given criteria for local similarity are included in the matrix as a means of reducing the necessary search space and thereby increasing efficiency. A number of similarity metrics are possible; the original definition of the CE method included only structural superpositions and inter-residue distances but has since been expanded to include local environmental properties such as secondary structure, solvent exposure, hydrogen-bonding patterns, and dihedral angles. An alignment path is calculated as the optimal path through the similarity matrix by linearly progressing through the sequences and extending the alignment with the next possible high-scoring AFP pair. The initial AFP pair that nucleates the alignment can occur at any point in the sequence matrix. Extensions then proceed with the next AFP that meets given distance criteria restricting the alignment to low gap sizes. The size of each AFP and the maximum gap size are required input parameters but are usually set to empirically determined values of 8 and 30 respectively.
Sources: en.wikipedia.org
=== Possible health risks === Some evidence suggests that T. molitor may pose a health risk, as humans and animals can consume the eggs and larvae of the beetle with grain-based food. Although they are usually either digested or are excreted with feces, sometimes, they are able to survive and live in the alimentary tract. The first cases of T. molitor larvae in human organs date back to the 19th century, where their presence was observed in the gastrointestinal tract, including the stomach and intestines. There were other cases, such as a reported ulcer infestation of T. molitor in an AIDS patient and a concerned urinary canthariasis in a ten-year-old boy in Iran in 2019, which was the last reported human case of canthariasis caused by T. molitor. However, there are very few reported cases of live larvae in animals, and there are no reports of gastrointestinal canthariasis in farm animals. A study analysing the results of patients in Poland for the presence of specific IgE antibodies to the mealworm was conducted prior to its widespread introduction as a food ingredient. Sensitisation to the mealworm was detected in 4.3% of the patients, with monosensitisation occurring rarely and affecting 0.7% of this group. It was determined that the presence of antibodies to the mealworm most often co-occurs with sensitization to other edible insects, such as the house cricket and the migratory locust, as well as to tropomyosins from shrimp and house dust mites. The primary or cross-sensitization may differ in different populations depending on the dietary habits or geographical zone.
== External links == NAS Report: The Health Effects of Perchlorate Ingestion NRDC's criticism of NAS report Environment California report Archived 2010-06-09 at the Wayback Machine (Executive Summary with link to full text) Macho Moms: Perchlorate pollutant masculinizes fish: Science News Online, August 12, 2006 Archived February 20, 2008, at the Wayback Machine New Scientist Space Blog: Phoenix discovery may be bad for Mars life State Threatening to Sue Military over Water Pollution Archived 2005-11-09 at the Wayback Machine, Associated Press, May 19, 2003. Health Effects of Perchlorate from Spent Rocket, SpaceDaily.com, July 11, 2002. Dept of Defense, Dept of Energy, and US Environmental Protection Agency's Strategic Environmental Research and Development Program, Elimination of Perchlorate Oxidizers from Pyrotechnic Flare Compositions, 2009 Archived 2007-08-06 at the Wayback Machine
== N-terminal modifications == Protein N-termini can be modified co - or post-translationally. Modifications include the removal of initiator methionine (iMet) by aminopeptidases, attachment of small chemical groups such as acetyl, propionyl and methyl, and the addition of membrane anchors, such as palmitoyl and myristoyl groups
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.